En studie av Alisertib i kombinasjon med endokrin terapi hos pasienter med HR-positiv, HER2-negativ tilbakevendende eller metastatisk brystkreft (ALISCA-Breast1)
En fase 2-studie av Alisertib i kombinasjon med endokrin terapi hos pasienter med HR+, HER2-negativ tilbakevendende eller metastatisk brystkreft
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy. Participants randomized prior to Amendment 4 are randomized 1:1:1 to Arm 1, Arm 2 or Arm 3. Participants randomized under Amendment 4 will be randomized 1:1 to Arm 1 or Arm 2.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Puma Biotechnology, Inc. Clinical Operations Senior Director
- Telefonnummer: 424-248-6500
- E-post: ClinicalTrials@pumabiotechnology.com
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 34235
- Rekruttering
- Alabama Oncology
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85054
- Rekruttering
- Mayo Clinic Hospital
-
-
California
-
Beverly Hills, California, Forente stater, 90211
- Rekruttering
- Beverly Hills Cancer Center
-
Fountain Valley, California, Forente stater, 92708
- Rekruttering
- MemorialCare Orange Coast Medical Center
-
Irvine, California, Forente stater, 92618
- Rekruttering
- City of Hope at Orange County Lennar Foundation Cancer Center
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- UCLA Department of Medicine - Hematology/Oncology
-
Los Angeles, California, Forente stater, 90017
- Rekruttering
- LA Cancer Network
-
San Francisco, California, Forente stater, 94158
- Rekruttering
- University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- University of Colorado School of Medicine
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06520
- Tilbaketrukket
- Yale University, Yale Cancer Center
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32256
- Rekruttering
- Cancer Specialists of North Florida
-
Jacksonville, Florida, Forente stater, 32224
- Rekruttering
- Mayo Clinic Florida
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Winship Cancer Institute, Emory University
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60612
- Rekruttering
- University of Illinois Cancer Center
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- The University of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Dana-Farber Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
- Rekruttering
- University of Minnesota, Masonic Cancer Center
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Mayo Clinic
-
-
Missouri
-
Columbia, Missouri, Forente stater, 65201
- Rekruttering
- Missouri Cancer Associates
-
Kansas City, Missouri, Forente stater, 64111
- Rekruttering
- Saint Luke's Cancer Institute
-
Springfield, Missouri, Forente stater, 65807
- Rekruttering
- Oncology Hematology Associates
-
St Louis, Missouri, Forente stater, 63110
- Rekruttering
- Washington University School of Medicine
-
-
Nevada
-
Reno, Nevada, Forente stater, 89511
- Rekruttering
- Cancer Care Specialists
-
-
New York
-
Rochester, New York, Forente stater, 14642
- Rekruttering
- University of Rochester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27514
- Rekruttering
- UNC Hospitals, University of North Carolina at Chapel Hill
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43212
- Rekruttering
- The Ohio State University, Stefanie Spielman Comprehensive Breast Center
-
Maumee, Ohio, Forente stater, 43537
- Rekruttering
- Taylor Cancer Research Center
-
-
Pennsylvania
-
Horsham, Pennsylvania, Forente stater, 19044
- Rekruttering
- Alliance Cancer Specialists
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Rekruttering
- University of Pittsburgh (UPMC)
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Tennessee Oncology, Greco-Hainsworth Center for Research
-
-
Texas
-
Dallas, Texas, Forente stater, 75246
- Rekruttering
- Texas Oncology
-
-
Virginia
-
Richmond, Virginia, Forente stater, 23229
- Rekruttering
- Virginia Cancer Institute
-
-
-
-
-
Lisbon, Portugal, 1998-018
- Rekruttering
- Hospital CUF Descobertas
-
Lisbon, Portugal, 1099-023
- Rekruttering
- Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa)
-
Lisbon, Portugal, 1400-038
- Rekruttering
- Fundação Champalimaud
-
Porto, Portugal, 4200-072
- Rekruttering
- Instituto Português Oncologia Do Porto
-
-
-
-
-
Alicante, Spania, 03010
- Rekruttering
- Hospital General Universitario Dr. Balmis
-
Barakaldo, Spania, 48903
- Rekruttering
- Hospital Universitario de Cruces
-
Barcelona, Spania, 08035
- Rekruttering
- Hospital Universitario Vall d'Hebron
-
Barcelona, Spania, 08036
- Rekruttering
- Hospital Clínico de Barcelona
-
Bilbao, Spania, 48013
- Rekruttering
- Hospital Universitario de Basurto
-
Cáceres, Spania, 10003
- Rekruttering
- Hospital San Pedro de Alcántara
-
Granada, Spania, 18012
- Rekruttering
- Hospital San Cecilio
-
Huelva, Spania, 21005
- Rekruttering
- Hospital Universitario Juan Ramon Jimenez
-
Jaén, Spania, 23007
- Rekruttering
- Hospital Universitario de Jaén
-
Lleida, Spania, 25198
- Rekruttering
- Hospital Universitario Arnau de Vilanova
-
Madrid, Spania, 28040
- Rekruttering
- Hospital Universitario Fundación Jiménez Díaz
-
Seville, Spania, 41013
- Rekruttering
- Hospital Universitario Virgen del Rocío
-
Valencia, Spania, 46010
- Rekruttering
- Hospital Clínico Universitario de Valencia
-
Valencia, Spania, 46009
- Rekruttering
- Fundación Instituto Valenciano de Oncología (IVO)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Aged ≥18 years at signing of informed consent.
- Pathology-confirmed diagnosis of breast cancer with evidence of recurrent or metastatic disease not amenable to curative therapy.
- Progression on or after treatment with at least two prior lines of endocrine therapy in the recurrent or metastatic setting. a. If metastatic disease recurrence occurs during or within six months of discontinuing adjuvant endocrine therapy, then that endocrine therapy will count as one line of prior therapy.
- Participants must have received a CDK4/6i in combination with endocrine therapy in the recurrent or metastatic setting.
- HR-positive and HER2-negative tumor status reported per local laboratory testing. HR and HER2 testing must be performed consistent with current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) or European Society of Medical Oncology (ESMO) guidelines.
Exclusion Criteria:
- Treatment with chemotherapy in the recurrent or metastatic setting, including antibody drug conjugates with a chemotherapeutic payload.
- Prior treatment with an Aurora Kinase A (AURKA) specific-targeted or pan-Aurora-targeted agent, including alisertib, in any setting.
Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Alisertib 50 mg
Alisertib with selected endocrine therapy |
Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
Andre navn:
Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information. 1 mg of anastrozole tablet by mouth once daily or 2.5 mg of letrozole tablet by mouth once daily or 25 mg of exemestane tablet by mouth once daily or 20 mg of tamoxifen tablet by mouth once daily or 500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter |
|
Eksperimentell: Alisertib 40 mg
Alisertib with selected endocrine therapy |
Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
Andre navn:
Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information. 1 mg of anastrozole tablet by mouth once daily or 2.5 mg of letrozole tablet by mouth once daily or 25 mg of exemestane tablet by mouth once daily or 20 mg of tamoxifen tablet by mouth once daily or 500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter |
|
Eksperimentell: Alisertib 30 mg
Alisertib with selected endocrine therapy Cohort closed to enrollment in Amendment 4 |
Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
Andre navn:
Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information. 1 mg of anastrozole tablet by mouth once daily or 2.5 mg of letrozole tablet by mouth once daily or 25 mg of exemestane tablet by mouth once daily or 20 mg of tamoxifen tablet by mouth once daily or 500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR) Within Dose Subgroup
Tidsramme: From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
Objective response rate is defined as the percentage of participants demonstrating a confirmed objective response during the study. |
From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
|
Duration of Response (DOR) Within Dose Subgroup
Tidsramme: From start date of response (after date of randomization) to first PD, assessed up to 48 months
|
Duration of response is measured from the time at which measurement criteria are first met for Complete Response (CR) or Partial Response (PR) (whichever status is recorded first) until the first date of recurrence or progressive disease (PD) or death is objectively documented. |
From start date of response (after date of randomization) to first PD, assessed up to 48 months
|
|
Disease Control Rate (DCR) Within Dose Subgroup
Tidsramme: From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
Disease control rate is the proportion of participants who achieve overall tumor response (confirmed CR or PR) or Stable Disease (SD) lasting for at least 24 weeks from randomization. |
From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
|
Progression Free Survival (PFS) Within Dose Subgroup
Tidsramme: From date of randomization to date of recurrence, progression or death, assessed up to 48 months
|
Progression Free Survival (PFS) is measured in months and based on the local tumor assessment. The time interval from the date of randomization until the first date on which recurrence, progression, or death due to any cause, is documented. |
From date of randomization to date of recurrence, progression or death, assessed up to 48 months
|
|
Overall Survival (OS) Within Dose Subgroup
Tidsramme: From date of randomization to death, assessed up to 48 months
|
Overall survival (OS) is defined as the time from randomization to death due to any cause, censored at the last date known alive on or prior to the data cutoff employed for the analysis, whichever was earlier. |
From date of randomization to death, assessed up to 48 months
|
|
Percentage of Participants With Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events) in the Enrolled Population
Tidsramme: From date of first dose through last dose plus 28 days, assessed up to 48 months
|
Treatment emergent adverse events are those events reported on or after the first dose of investigational product and up to 28 days after last dose. |
From date of first dose through last dose plus 28 days, assessed up to 48 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR) Within Biomarker-Defined Subgroup
Tidsramme: From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
Objective response rate is defined as the percentage of participants demonstrating a confirmed objective response during the study. |
From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
|
Duration of Response (DOR) Within Biomarker-Defined Subgroup
Tidsramme: From start date of response (after date of randomization) to first PD, assessed up to 48 months
|
Duration of response is measured from the time at which measurement criteria are first met for CR or PR (whichever status is recorded first) until the first date of recurrence or progressive disease (PD) or death is objectively documented. |
From start date of response (after date of randomization) to first PD, assessed up to 48 months
|
|
Disease Control Rate (DCR) Within Biomarker-Defined Subgroup
Tidsramme: From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
Disease control rate is the proportion of participants who achieve overall tumor response (confirmed CR or PR) or SD lasting for at least 24 weeks from randomization. |
From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
|
Progression Free Survival (PFS) Within Biomarker-Defined Subgroup
Tidsramme: From date of randomization to date of recurrence, progression or death, assessed up to 48 months
|
Progression Free Survival (PFS) is measured in months and based on the local tumor assessment. The time interval from the date of randomization until the first date on which recurrence, progression, or death due to any cause, is documented. |
From date of randomization to date of recurrence, progression or death, assessed up to 48 months
|
|
Overall Survival (OS) Within Biomarker-Defined Subgroup
Tidsramme: From date of randomization to death, assessed up to 48 months
|
Overall survival (OS) is defined as the time from randomization to death due to any cause, censored at the last date known alive on or prior to the data cutoff employed for the analysis, whichever was earlier. |
From date of randomization to death, assessed up to 48 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Chief Reg Affairs, PV, Medical Affairs and Law Officer, Puma Biotechnology, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PUMA-ALI-1201
- 2024-511497-79-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Puma Biotechnology is committed to sharing clinical trial data and information to help physicians and patients make informed treatment decisions, and to help qualified researchers advance scientific knowledge.
In accordance with legal and regulatory requirements, Puma publishes study protocol information and clinical study results on clinical trial registries, including ClinicalTrials.gov and EU Clinical Trials Register. Puma also publishes information about clinical studies in peer-reviewed scientific journals and shares data in scientific meetings.
Puma commits to safeguarding confidentiality and patient privacy throughout the clinical trial data and information sharing process. Any patient-level data will be anonymized to protect personally identifiable information.
Qualified researchers and study participants may submit requests for other study documentation and clinical trial data to clinicaltrials@pumabiotechnology.com for consideration.
IPD-delingstidsramme
Clinical study documents and clinical trial data may be requested by qualified researchers and study participants for studies that have been completed for at least 18 months, and for which the indication of the drug has been approved in the US and/or EU, as applicable. Requests will be accepted for up to 24 months after the criteria described in this section are met.
Tilgangskriterier for IPD-deling
Requestors must provide organizational contact information; a detailed research plan, including outcomes; timeline for completion of the research; qualifications of the research team; funding source; and potential conflicts of interest.
Puma will not provide access to patient-level data if there is a reasonable likelihood that individual patients could be identified, or in cases where confidentiality or consent provisions prohibit transfer of data or information to third parties. Additionally, Puma will not disclose information that jeopardizes intellectual property rights or divulges confidential commercial information.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .